立即打开
近100万美国儿童在过去四周内感染新冠

近100万美国儿童在过去四周内感染新冠

Brett Haensel 2021年09月27日
自从新冠疫情流行以来,总共有550万名美国儿童的新冠病毒检测呈阳性。

美国儿科学会(American Academy of Pediatrics)和儿童医院协会(Children’s Hospital Association)于9月20日发布的一份报告显示,随着更具传染性的德尔塔变种病毒继续在返校学生中传播,感染新冠病毒的儿童数量正在呈“指数级”上升。

美国儿科学会报告说,在截至9月16日的过去一周内,有近226000例新的儿童病例,这是自新冠疫情开始以来一周内第三高的儿童病例数。上周报告的所有病例中,儿童占25.7%,尽管自新冠疫情爆发以来,儿童仅占所有新冠肺炎病例的15.7%,占美国人口的22.2%。

上周报告的儿童病例数较7月15日至22日期间报告的约39000例增加了480%,这进一步表明在夏季的最后几个月里,新冠疫情的形势逐渐严峻。

美国儿科学会在报告中说:“初夏时期,新冠肺炎病例数下降之后,儿童病例数呈指数级增长,在过去四周内超过92.5万例。”自从新冠疫情流行以来,总共有550万名美国儿童的新冠病毒检测呈阳性。

目前,美国只有12岁及以上的儿童才有资格接种新冠疫苗。不过,因为辉瑞(Pfizer)的疫苗和BioNTech的疫苗预计将为更年幼的儿童申请紧急批准,5岁至11岁的儿童也将拥有接种疫苗的资格。

因为美国各州和学区的关于强制戴口罩的政策各不相同并且德尔塔变种病毒继续感染人群,卫生官员仍然担心今年秋天新冠病毒会在教室里的儿童群体中进一步传播。白宫首席医疗顾问安东尼·福奇博士于一个多星期前在伦敦卫生与热带医学院(London School of Hygiene and Tropical Medicine)主办的一次演讲中表示,他担心德尔塔变种病毒对未接种疫苗的儿童造成影响。

“我们的医院几乎不堪重负。目前有很多孩子在医院里。”福奇说。“尽管相对而言,与成年人相比,他们的病情没有那么严重,但死于新冠病毒的儿童比死于流感的儿童更多,我们却只给儿童接种了流感疫苗。”

虽然儿童因为新冠肺炎而住院的比例确实高于初夏时期,但在报告数据的24个州中,儿童病例仅占新冠肺炎患者住院总人数的1.6%至4.2%。

总体而言,0.1%至2%的儿童病例住院,在报告中各州的数据显示,儿童病例占新冠肺炎死亡病例的比例不超过0.25%。相对而言,该病毒对儿童的长期影响仍然未知。

美国儿科学会在报告中说:“目前,新冠疫情导致的严重疾病在儿童中似乎不常见。然而,我们迫切需要收集更多关于新冠疫情对儿童的长期影响的数据,包括对感染新冠病毒的儿童的身体健康以及对儿童情绪和心理健康的影响。”

儿童疫苗的时间表

辉瑞和BioNTech公司正在推动美国和欧盟(European Union)的监管机构迅速批准它们针对5岁及以上儿童的新冠疫苗。BioNTech公司的首席执行官乌古尔·萨欣在一份声明中说,对这一群体的测试已经得出了与老年群体一致的结果。

正如《财富》杂志的资深撰稿人戴维·梅耶在9月21日的报道中所述,制药商在对幼儿进行疫苗试验时,必须考虑几个因素,其中之一就是接种剂量。以辉瑞和BioNTech公司的疫苗为例,5岁至11岁的儿童将接种10微克的新冠疫苗,这是12岁及以上儿童接种量的三分之一。

这些公司还表示,它们希望“最快在今年第四季度”提供新冠疫苗对2岁至 5岁,以及6个月至2岁人群的安全性和有效性的测试结果。(财富中文网)

编译:於欣

美国儿科学会(American Academy of Pediatrics)和儿童医院协会(Children’s Hospital Association)于9月20日发布的一份报告显示,随着更具传染性的德尔塔变种病毒继续在返校学生中传播,感染新冠病毒的儿童数量正在呈“指数级”上升。

美国儿科学会报告说,在截至9月16日的过去一周内,有近226000例新的儿童病例,这是自新冠疫情开始以来一周内第三高的儿童病例数。上周报告的所有病例中,儿童占25.7%,尽管自新冠疫情爆发以来,儿童仅占所有新冠肺炎病例的15.7%,占美国人口的22.2%。

上周报告的儿童病例数较7月15日至22日期间报告的约39000例增加了480%,这进一步表明在夏季的最后几个月里,新冠疫情的形势逐渐严峻。

美国儿科学会在报告中说:“初夏时期,新冠肺炎病例数下降之后,儿童病例数呈指数级增长,在过去四周内超过92.5万例。”自从新冠疫情流行以来,总共有550万名美国儿童的新冠病毒检测呈阳性。

目前,美国只有12岁及以上的儿童才有资格接种新冠疫苗。不过,因为辉瑞(Pfizer)的疫苗和BioNTech的疫苗预计将为更年幼的儿童申请紧急批准,5岁至11岁的儿童也将拥有接种疫苗的资格。

因为美国各州和学区的关于强制戴口罩的政策各不相同并且德尔塔变种病毒继续感染人群,卫生官员仍然担心今年秋天新冠病毒会在教室里的儿童群体中进一步传播。白宫首席医疗顾问安东尼·福奇博士于一个多星期前在伦敦卫生与热带医学院(London School of Hygiene and Tropical Medicine)主办的一次演讲中表示,他担心德尔塔变种病毒对未接种疫苗的儿童造成影响。

“我们的医院几乎不堪重负。目前有很多孩子在医院里。”福奇说。“尽管相对而言,与成年人相比,他们的病情没有那么严重,但死于新冠病毒的儿童比死于流感的儿童更多,我们却只给儿童接种了流感疫苗。”

虽然儿童因为新冠肺炎而住院的比例确实高于初夏时期,但在报告数据的24个州中,儿童病例仅占新冠肺炎患者住院总人数的1.6%至4.2%。

总体而言,0.1%至2%的儿童病例住院,在报告中各州的数据显示,儿童病例占新冠肺炎死亡病例的比例不超过0.25%。相对而言,该病毒对儿童的长期影响仍然未知。

美国儿科学会在报告中说:“目前,新冠疫情导致的严重疾病在儿童中似乎不常见。然而,我们迫切需要收集更多关于新冠疫情对儿童的长期影响的数据,包括对感染新冠病毒的儿童的身体健康以及对儿童情绪和心理健康的影响。”

儿童疫苗的时间表

辉瑞和BioNTech公司正在推动美国和欧盟(European Union)的监管机构迅速批准它们针对5岁及以上儿童的新冠疫苗。BioNTech公司的首席执行官乌古尔·萨欣在一份声明中说,对这一群体的测试已经得出了与老年群体一致的结果。

正如《财富》杂志的资深撰稿人戴维·梅耶在9月21日的报道中所述,制药商在对幼儿进行疫苗试验时,必须考虑几个因素,其中之一就是接种剂量。以辉瑞和BioNTech公司的疫苗为例,5岁至11岁的儿童将接种10微克的新冠疫苗,这是12岁及以上儿童接种量的三分之一。

这些公司还表示,它们希望“最快在今年第四季度”提供新冠疫苗对2岁至 5岁,以及6个月至2岁人群的安全性和有效性的测试结果。(财富中文网)

编译:於欣

COVID cases among children are rising “exponentially,” according to a report released by the American Academy of Pediatrics (AAP) and the Children’s Hospital Association on September 20, as the more contagious Delta variant continues to wreak havoc with students returning to school.

The AAP reported nearly 226,000 new child cases over the past week ending Sept. 16—the third-highest number of child cases in a week since the pandemic began. Children accounted for 25.7% of all cases reported last week, despite representing just 15.7% of all COVID cases since the pandemic began and making up 22.2% of the U.S. population.

Further highlighting how much the situation has worsened over the final months of summer, last week’s pediatric cases mark a 480% increase over the roughly 39,000 new cases among children reported during the week of July 15 to 22.

“After declining in early summer, child cases have increased exponentially, with over 925,000 cases in the past 4 weeks,” the AAP said in the report. In total, 5.5 million U.S. children have tested positive for COVID-19 since the beginning of the pandemic.

Currently, only children ages 12 or older are eligible to receive the COVID vaccine in the United States. However, that eligibility could soon expand to ages 5 to 11, as Pfizer and BioNTech are expected to file for emergency approval for younger children.

Health officials remain concerned over further spread among children in the classroom this fall—with mask mandate policies varying by state and school district—while the Delta variant continues to infect people at high rates. White House chief medical adviser Dr. Anthony Fauci, when speaking at a lecture hosted by the London School of Hygiene and Tropical Medicine a little over a week ago, expressed concern over the impact the virus is having on children who remain unvaccinated.

“We are almost overrun. We have a lot of children in hospitals now,” Fauci said. “So even though relatively speaking, compared to an adult they don’t get as seriously ill, we have lost more children from SARS-CoV-2 than we ever lose for influenza—and we vaccinate children against influenza.”

While child hospitalizations due to COVID are indeed occurring at a higher rate than they did early in the summer, kids have made up only between 1.6% and 4.2% of overall COVID hospitalizations among the 24 states that reported data.

Overall, between 0.1% and 2% of pediatric cases result in hospitalization, and children have accounted for no more than 0.25% of COVID deaths among the states that reported that data. Longer-term effects of the virus on children are still relatively unknown.

“At this time, it appears that severe illness due to COVID-19 is uncommon among children,” the AAP said in the report. “However, there is an urgent need to collect more data on longer-term impacts of the pandemic on children, including ways the virus may harm the long-term physical health of infected children, as well as its emotional and mental health effects.”

Timelines on vaccines for kids

Pfizer and BioNTech are pushing for quick approval from U.S. and European Union regulators of their COVID vaccine for kids age 5 and older. BioNTech CEO Ugur Sahin said in a statement that tests on that group had produced results consistent with those in older populations.

As Fortune senior writer David Meyer reported on September 21, there are several considerations that the drugmakers have had to take into account when trialing the vaccine in younger children, one of which is the amount that is to be administered. In the case of Pfizer and BioNTech’s vaccine, kids between the ages of 5 and 11 will get 10-microgram doses, which is a third of the amount that people age 12 and older get.

The companies said they are also hoping to provide results on COVID vaccine safety and effectiveness for the 2- to 5-year-old and 6-month to 2-year-old cohorts “as soon as the fourth quarter of this year.”

最新:
  • 热读文章
  • 热门视频
活动
扫码打开财富Plus App
    <i id='ynDtMqRL'><i></i></i>
    <base id='ZsKcPKdq'><cite></cite></base><strong id='LhLRGvU'><strong></strong></strong><strike id='mAGTVF'><center></center></strike><xmp id='LV'><person></person></xmp><option id='vtbmU'><fieldset></fieldset></option>
        <big></big><person id='lkxWP'><dir></dir></person><xmp id='cGp'><kbd></kbd></xmp>
        <marquee></marquee>
        <s id='cmijoA'><comment></comment></s><span id='lRnrVu'><fieldset></fieldset></span>
          <samp id='ua'><dfn></dfn></samp>
            <sup id='idDNTWV'><xmp></xmp></sup>